Cancers & treatments·Regimen libraryFirst line

Abiraterone + prednisone with ADT

Checked 2026-09-09

High-risk metastatic hormone-sensitive (LATITUDE, STAMPEDE) or castration-resistant prostate cancer

One cycle

every 28 days

28-day cycle, until progressionOralSubcutaneous Daily oral course

Components

Drug	Dose	Route	Days
Abiraterone acetate Small-molecule CYP17A1 inhibitor	1,000 mg once daily on an empty stomach	Oral	D1-28
Prednisone	5 mg once daily (twice daily in castration-resistant disease)	Oral	D1-28
GnRH agonist or antagonist GnRH agonist depot	per depot schedule	SC	D1

Cycles

until progression

28-day cycle

Emetogenicity

Minimal (<10%)

G-CSF

Not routine

Notes

Food increases exposure up to tenfold; take at least 1 hour before or 2 hours after a meal.
Monitor potassium, blood pressure and liver enzymes; hypokalaemia and hypertension are mineralocorticoid effects.

Used in

Prostate cancer

Trials

LATITUDE STAMPEDE

Products

Abiraterone acetateLeuprolide (leuprorelin) and GnRH agonists

Source

LATITUDE, NEJM 2017

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.

Other regimens for these cancers

Docetaxel + prednisone

Metastatic hormone-sensitive (with ADT, 6 cycles: CHAARTED, ARASENS) or castration-resistant prostate cancer

every 21 days × 6

Cabazitaxel + prednisone

Metastatic castration-resistant prostate cancer after docetaxel and an AR-pathway inhibitor

every 21 days

177Lu-PSMA-617

PSMA PET-positive metastatic castration-resistant prostate cancer after an AR-pathway inhibitor (PSMAfore) and, in VISION, after taxane

every 42 days × 6

Olaparib maintenance

Newly diagnosed BRCA-mutant advanced ovarian cancer after platinum response (2 years); recurrent platinum-sensitive disease; BRCA/HRR-mutant prostate; germline BRCA pancreatic after platinum

every 28 days × 2

All regimens 177Lu-PSMA-617 →